| Pregnancy, Pediatrics
and HIV Infection: Guidelines for Your Practice Page 7
|
Findings
on Follow-up of Women Who Participated in
US PACTG 076 AZT vs Control Group
No difference in clinical disease
progression
No difference in AIDS cases or deaths
No difference in CD4 counts
|
|
| Infants who received follow-up
care had normal developmental scores. Both exposed and unexposed infants had adequate
growth patterns. There was no indication of an increased incidence of cancer among infants
who had perinatal exposure to AZT compared with those who did not. By matching New Jersey
HIV/AIDS Registry with the cancer registry, no increase in the incidence of tumors among
children who were exposed to AZT perinatally has been observed; however, there remains a
potential for birth defects. To date, birth defects associated with AZT have not been
detected in New Jersey. |
| Blanche et al revealed that 8 of
3000 children who had been exposed to antiretroviral agents in the perinatal period
developed mitochondrial toxicity.3 This
report prompted a retrospective review of medical records in the United States, Thailand,
Africa, and Europe (except France).4 Of
27,000 medical records, none revealed evidence of mitochondrial toxicity related to
perinatal use of AZT. In New Jersey, there has been no evidence of AZT-related
mitochondrial toxicity of children. |
Findings
on Follow-up of Infants Who Participated in
US PACTG 076 AZT vs Control Group
Both groups had normal developmental scores
Both had adequate growth patterns
No increased incidence of cancer among
exposed children up to age 5
No evidence of mitochondrial toxicity in
children who received PACTG 076 regimen in US
|
|
| Continue
to Next Page
Back to Course Listing | AMNJ
Online CME |